Blueprint Medicines Corporation Stock News

Blueprint Medicines' (BPMC) earnings and revenues trump estimates for the third quarter of 2022. The company lowers product revenue guidance for Ayvakit.

Blueprint Medicines (BPMC) expects its lead drug, Ayvakit, which is approved to treat rare cancer and other rare diseases, to generate incremental sales and combat stiff competition.

Blueprint Medicines (BPMC) expects its lead drug, Ayvakit, which is approved to treat rare cancer and other rare diseases, to generate incremental sales and combat stiff competition.

Deciphera's (DCPH) Qinlock, approved for treating advanced gastrointestinal stromal tumors, has seen strong uptake since its approval. The recent restructuring initiative is saving costs.

Blueprint has a few recently approved therapies, and has recently sold royalties for over $1 billion. While this limits revenue potential now, the profits can be leveraged back into advancing the pipe

Upgrades For Iris Energy Ltd (NASDAQ:IREN), Compass Point upgraded the previous rating of Neutral to Buy. The current stock performance of Iris Energy shows a 52-week-high of $17.97 and a 52-week-low

Blueprint Medicines' (BPMC) Ayvakit, approved for treating PDGFRA Exon 18 mutant gastrointestinal stromal tumors, is witnessing strong uptake. The drug's label expansion studies also hold promise.

Blueprint Medicines' (BPMC) Ayvakit, approved for treating PDGFRA Exon 18 mutant gastrointestinal stromal tumors, is witnessing strong uptake. The drug's label expansion studies also hold promise.

Analysts have provided the following ratings for Blueprint Medicines (NASDAQ:BPMC) within the last quarter: Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 5 2 6 1

Exelixis (EXEL) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Reata Pharmaceuticals, Inc. (RETA) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Regeneron (REGN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Blueprint Medicines (BPMC) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Deciphera's (DCPH) Qinlock, approved for treating advanced gastrointestinal stromal tumors, has seen strong uptake since its approval. However, heavy dependence on Qinlock for growth remains a woe.

Blueprint Medicines (NASDAQ:BPMC) has observed the following analyst ratings within the last quarter: Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 6 1 5 1 1 L